The first BiTE, blinatumomab, was approved by the FDA in 2014 for relapsed or refractory (R/R) CD19+ B-cell precursor acute lymphoblastic leukemia (ALL). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.